Table 4 ICU admission characteristics by maximal KDIGO-UO stage.

From: Toward the standardization of big datasets of urine output for AKI analysis: a multicenter validation study

Characteristic

MIMICdb

AUMCdb

No AKI N = 23,9721

Stage 1 N = 11,2621

Stage 2 N = 8,9911

Stage 3 N = 2,1191

p-value2

No AKI N = 10,2351

Stage 1 N = 2,4561

Stage 2 N = 1,5891

Stage 3 N = 6431

p-value2

Age at hospital admission, years

62 (18)

67 (16)

68 (16)

66 (16)

 < 0.001

62 (15)

65 (15)

68 (14)

66 (15)

 < 0.001

Weight at ICU admission, kg

77 (20)

84 (23)

89 (27)

88 (28)

 < 0.001

79 (14)

83 (15)

85 (15)

83 (16)

 < 0.001

Gender

    

 < 0.001

    

 < 0.001

 F

10,590 (44%)

4,710 (42%)

3,987 (44%)

963 (45%)

 

3,064 (31%)

879 (36%)

544 (35%)

231 (37%)

 

 M

13,382 (56%)

6,552 (58%)

5,004 (56%)

1,156 (55%)

 

6,933 (69%)

1,540 (64%)

1,028 (65%)

400 (63%)

 

Ethnicity

    

 < 0.001

     

 African American

2,051 (9.8%)

910 (9.3%)

840 (11%)

244 (14%)

      

 Asian

895 (4.3%)

232 (2.4%)

146 (1.9%)

59 (3.4%)

      

 Caucasian

16,023 (76%)

7,795 (80%)

6,228 (80%)

1,268 (73%)

      

 Hispanic

935 (4.5%)

325 (3.3%)

243 (3.1%)

67 (3.9%)

      

 Other

1,053 (5.0%)

471 (4.8%)

336 (4.3%)

95 (5.5%)

      

CCI score

4 (2, 6)

5 (3, 7)

5 (3, 7)

6 (4, 8)

 < 0.001

     

CKD, stage 1–4

3,101 (13%)

1,802 (16%)

1,879 (21%)

799 (38%)

 < 0.001

     

Diabetes mellitus

4,933 (21%)

2,662 (24%)

2,201 (24%)

508 (24%)

 < 0.001

     

SOFA score at ICU admission

3 (1, 5)

4 (2, 6)

4 (2, 7)

8 (4, 12)

 < 0.001

     

SAPS-II at ICU admission

30 (22, 38)

33 (26, 42)

37 (29, 47)

49 (37, 60)

 < 0.001

     

APS-III at ICU admission

34 (26, 44)

38 (29, 50)

43 (33, 58)

64 (45, 83)

 < 0.001

     

First sCr in ICU, mg/dL

1.14 (1.04)

1.19 (1.02)

1.42 (1.51)

2.87 (2.81)

 < 0.001

1.07 (0.65)

1.19 (0.93)

1.44 (1.50)

2.40 (2.42)

 < 0.001

Peak sCr at first days, mg/dL

1.21 (1.07)

1.33 (1.10)

1.70 (1.70)

3.79 (3.07)

 < 0.001

1.06 (0.64)

1.29 (0.94)

1.92 (1.59)

3.74 (1.98)

 < 0.001

ICU discharge sCr, mg/dL

1.00 (0.79)

1.12 (0.95)

1.40 (1.38)

2.92 (2.46)

 < 0.001

0.95 (0.50)

1.07 (0.81)

1.41 (1.20)

2.30 (1.50)

 < 0.001

Peak KDIGO-Cr at first days

    

 < 0.001

     

 0

20,132 (86%)

8,387 (75%)

5,646 (63%)

711 (34%)

      

 1

2708 (12%)

2,166 (19%)

2,247 (25%)

639 (30%)

      

 2

440 (1.9%)

369 (3.3%)

569 (6.4%)

204 (9.7%)

      

 3

175 (0.7%)

198 (1.8%)

454 (5.1%)

544 (26%)

      

Time in hospital, days

6.0 (3.0, 10.0)

7.0 (4.0, 12.0)

8.0 (5.0, 13.0)

10.0 (5.0, 18.0)

 < 0.001

     

Time in ICU, days

1.4 (1.0, 2.5)

2.2 (1.3, 4.0)

2.9 (1.8, 5.1)

4.4 (2.8, 8.2)

 < 0.001

1.0 (0.9, 2.0)

2.5 (1.0, 6.9)

4.7 (2.1, 11.3)

7.2 (3.0, 18.2)

 < 0.001

Renal replacement therapy

281 (1.2%)

257 (2.3%)

604 (6.7%)

970 (46%)

 < 0.001

44 (0.4%)

61 (2.5%)

213 (13%)

483 (75%)

 < 0.001

Hospital mortality

1,163 (4.9%)

1,005 (8.9%)

1,440 (16%)

671 (32%)

 < 0.001

424 (4.1%)

310 (13%)

389 (24%)

308 (48%)

 < 0.001

  1. CCI charlson comorbidity index, CKD Stage 1–4 chronic kidney disease excluding end-stage-renal-disease, sCr serum creatinine, DM diabetes mellitus, ICU intensive care unit, SOFA sequential organ failure assessment.
  2. 1Mean (SD); n (%); Median (Q1, Q3).
  3. 2One-way analysis of means; Pearson’s Chi-squared test; Kruskal–Wallis rank sum test.
Back to article page